Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA2 | P00918 | 4/20 | 0.58 |
| ▸ | CA12 | O43570 | 3/20 | 0.58 |
| ▸ | CA1 | P00915 | 3/20 | 0.58 |
| ▸ | CA9 | Q16790 | 3/20 | 0.58 |
| ▸ | CA3 | P07451 | 2/20 | 0.58 |
| ▸ | CA4 | P22748 | 2/20 | 0.58 |
| ▸ | CA6 | P23280 | 2/20 | 0.58 |
| ▸ | CA5A | P35218 | 2/20 | 0.58 |
| ▸ | CA7 | P43166 | 2/20 | 0.58 |
| ▸ | CA13 | Q8N1Q1 | 2/20 | 0.58 |
| ▸ | CA14 | Q9ULX7 | 2/20 | 0.58 |
| ▸ | CA5B | Q9Y2D0 | 2/20 | 0.58 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.56 |
| ▸ | GLA | P06280 | 1/20 | 0.56 |
| ▸ | CISD1 | Q9NZ45 | 1/20 | 0.47 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.46 |
| ▸ | MCL1 | Q07820 | 1/20 | 0.46 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.46 |
| ▸ | CES2 | O00748 | 1/20 | 0.46 |
| ▸ | GALR3 | O60755 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1725674 | 0.85 | CA12 (0.58) | CA2CA12CA1CA9CA3 | |
| SCHEMBL8775824 | 0.81 | KDM4E (0.52) | CA2CA12CA1CA9CA3 | |
| SCHEMBL26580541 | 0.81 | KDM4E (0.52) | CA2CA12CA1CA9CA3 | |
| SCHEMBL19202355 | 0.80 | CA2 (0.61) | CA2CA12CA1CA9CA5A | |
| SCHEMBL11153098 | 0.78 | CA2 (0.58) | CA2CA12CA1CA9CA3 | |
| SCHEMBL3526722 | 0.78 | KEAP1 (0.56) | CA2CA12CA1CA9CA3 | |
| SCHEMBL1684416 | 0.77 | MCL1 (0.50) | KDM4EGLAMCL1CES2GALR3 | |
| SCHEMBL13278054 | 0.77 | CES2 (0.42) | CA2CA12CA1CA9CA3 | |
| SCHEMBL570906 | 0.76 | KDM4E (0.63) | KDM4EGLACYP2C9HSD17B10CES2 | |
| SCHEMBL16098104 | 0.75 | PTGS2 (0.51) | CA12CA9KDM4EGLAMCL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11999758-B2 | Inhibitors of the YAP/TAZ-TEAD interaction and their use in the treatment of cancer | INVENTIVA (FR) | 2024-06-04 | — | — | US | disclosed |
| CN-113039182-B | Inhibitors of YAP/TAZ-TEAD interactions and their use in cancer treatment | 伊文蒂瓦公司 | 2024-02-20 | — | — | CN | disclosed |
| EP-3860990-B1 | INHIBITORS OF THE YAP/TAZ-TEAD INTERACTION AND THEIR USE IN THE TREATMENT OF CANCER | INVENTIVA (FR) | 2022-09-14 | — | — | EP | disclosed |
| US-20210323982-A1 | INHIBITORS OF THE YAP/TAZ-TEAD INTERACTION AND THEIR USE IN THE TREATMENT OF CANCER | INVENTIVA (FR) | 2021-10-21 | — | — | US | disclosed |
| EP-3860990-A1 | INHIBITORS OF THE YAP/TAZ-TEAD INTERACTION AND THEIR USE IN THE TREATMENT OF CANCER | Inventiva (FR) | 2021-08-11 | — | — | EP | disclosed |
| CN-113039182-A | Inhibitors of YAP/TAZ-TEAD interaction and their use in cancer treatment | 伊文蒂瓦公司 | 2021-06-25 | — | — | CN | disclosed |
| WO-2020070181-A1 | INHIBITORS OF THE YAP/TAZ-TEAD INTERACTION AND THEIR USE IN THE TREATMENT OF CANCER | INVENTIVA (FR) | 2020-04-09 | — | — | WO | disclosed |
| EP-3632908-A1 | INHIBITORS OF THE YAP/TAZ-TEAD INTERACTION AND THEIR USE IN THE TREATMENT OF CANCER | Inventiva (FR) | 2020-04-08 | — | — | EP | disclosed |
| EP-2976340-B1 | CYCLOALKYL NITRILE PYRAZOLO PYRIDONES AS JANUS KINASE INHIBITORS | MERCK SHARP & DOHME (US) | 2018-06-13 | — | — | EP | disclosed |
| US-9725445-B2 | Cycloalkyl nitrile pyrazolo pyridones as Janus kinase inhibitors | MERCK SHARP & DOHME CORP. (US) | 2017-08-08 | — | — | US | disclosed |
| US-20160280704-A1 | CYCLOALKYL NITRILE PYRAZOLO PYRIDONES AS JANUS KINASE INHIBITORS | MERCK SHARP & DOHME CORP. (US) | 2016-09-29 | — | — | US | disclosed |
| EP-2976340-A1 | CYCLOALKYL NITRILE PYRAZOLO PYRIDONES AS JANUS KINASE INHIBITORS | Merck Sharp & Dohme Corp. (US) | 2016-01-27 | — | — | EP | disclosed |
| WO-2014146490-A1 | CYCLOALKYL NITRILE PYRAZOLO PYRIDONES AS JANUS KINASE INHIBITORS | MERCK SHARP & DOHME CORP. (US) | 2014-09-25 | — | — | WO | disclosed |
| WO-2014146246-A1 | CYCLOALKYL NITRILE PYRAZOLO PYRIDONES AS JANUS KINASE INHIBITORS | MERCK SHARP & DOHME CORP. (US) | 2014-09-25 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210323982-A1 | INHIBITORS OF THE YAP/TAZ-TEAD INTERACTION AND THEIR USE IN THE TREATMENT OF CANCER | YAP1, TEAD2, YES1 | CA2 3706/4885CA12 4740/4885CA1 4802/4885 |
| US-11999758-B2 | Inhibitors of the YAP/TAZ-TEAD interaction and their use in the treatment of cancer | YAP1, TEAD2, YES1 | CA2 3706/4885CA12 4740/4885CA1 4802/4885 |
| US-20160280704-A1 | CYCLOALKYL NITRILE PYRAZOLO PYRIDONES AS JANUS KINASE INHIBITORS | JAK1, JAK3, JAK2 | CA2 4032/4885CA12 4822/4885CA1 4489/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.